Zanubrutinib + R-CHOP

Zanubrutinib + R-CHOP is a combination therapy regimen primarily used for treating various subtypes of diffuse large B-cell lymphoma (DLBCL). This regimen combines zanubrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, with the standard R-CHOP chemotherapy protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). ## Efficacy and Applications The combination has shown promising results in several clinical trials, particularly for specific DLBCL subtypes: - For double-expressor lymphoma (DEL) patients, the objective response rate (ORR) was 89.6%, with a complete response rate (CRR) of 83.3%[2] - In non-GCB DLBCL patients with extranodal involvement, the regimen demonstrated a 96% objective response rate[1] - For DLBCL patients with MYD88L265P and CD79B mutations (MCD subtype), the combination appears effective and well-tolerated[4] - In patients with double expression of MYC and BCL-2, the complete response rates were significantly higher with ZR-CHOP compared to R-CHOP alone (95% vs. 65.2% after 6 treatment cycles)[6][7] ## Administration Protocol The typical administration protocol includes: - Zanubrutinib: 160 mg orally twice daily throughout treatment cycles - R-CHOP: Standard dosing of rituximab (375mg/m²), cyclophosphamide (750mg/m²), doxorubicin (50mg/m²), vincristine (1.4mg/m²), and prednisone (50mg/day for 5 days)[1] ## Safety Profile The combination therapy has demonstrated an acceptable safety profile: - Common hematological toxicities include neutropenia, thrombocytopenia, and anemia[1] - Common non-hematological toxicities include pneumonia, nausea, and fatigue[1] - No increased risk of severe infection or hemorrhage has been reported when combining zanubrutinib with R-CHOP[5] - Grade ≥3 adverse events were reported in 47.9% of patients in one study[2] ## Clinical Development This combination is being actively studied in multiple clinical trials for various DLBCL subtypes, particularly those with poor prognosis with standard R-CHOP therapy alone. The addition of zanubrutinib to R-CHOP appears to improve outcomes without significantly increasing toxicity, making it a promising approach for difficult-to-treat lymphoma subtypes.

Other names

ZR-CHOP